Literature DB >> 6358121

Abnormal serum factors in Guillain-Barré syndrome.

R P Lisak, M J Brown, A J Summer.   

Abstract

The Guillain-Barré Syndrome (GBS) is generally considered to be a cell-mediated immunopathologic disease of the peripheral nervous system (PNS), although the evidence for this is indirect. Both in vitro and in vivo studies of sera from experimental animals with autoimmune demyelinating neuropathies suggest that serum factors, including antibodies to PNS myelin and/or Schwann cells, may be important in the pathogenesis of some of these disorders. More recently, similar in vitro and in vivo techniques, including the production of demyelination following intraneural injection in the rat have been employed to study sera from patients with GBS. The results of these studies demonstrate the presence of factor(s), as yet not fully characterized, that may be important in mediating demyelination. Moreover, in some patients with chronic or relapsing demyelinative inflammatory neuropathies and monoclonal gammopathy, there is evidence of antimyelin antibodies to PNS myelin. Further studies of serum from patients with acute GBS and these other neuropathies may clarify the role of serum factors in acquired inflammatory diseases of the PNS.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6358121     DOI: 10.1007/bf02043478

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  70 in total

1.  Cellular hypersensitivity to basic myelin (P2) protein in the Guillain-Barré syndrome.

Authors:  W Sheremata; S Colby; Y Karkhanis; E H Eylar
Journal:  Can J Neurol Sci       Date:  1975-05       Impact factor: 2.104

2.  Cold reactive antilymphocyte antibodies in neurological diseases.

Authors:  R P Lisak; F Mercado; B Zweiman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-11       Impact factor: 10.154

3.  A biological role for the major histocompatibility antigens.

Authors:  P C Doherty; R M Zinkernagel
Journal:  Lancet       Date:  1975-06-28       Impact factor: 79.321

4.  Complement activation by isolated myelin: activation of the classical pathway in the absence of myelin-specific antibodies.

Authors:  P Vanguri; C L Koski; B Silverman; M L Shin
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

5.  Results of endoneural injection of Guillain-Barré serum in Lewis rats.

Authors:  P A Low; J D Schmelzer; P J Dyck
Journal:  Mayo Clin Proc       Date:  1982-06       Impact factor: 7.616

6.  Antiserum-mediated demyelination: relationship between remyelination and functional recovery.

Authors:  K Saida; A J Sumner; T Saida; M J Brown; D H Silberberg
Journal:  Ann Neurol       Date:  1980-07       Impact factor: 10.422

7.  Cerebroside antibody inhibits sulfatide synthesis and myelination and demyelinates in cord tissue cultures.

Authors:  J M Fry; S Weissbarth; G M Lehrer; M B Bornstein
Journal:  Science       Date:  1974-02-08       Impact factor: 47.728

8.  A search for antibodies against glial cells in the serum and cerebrospinal fluid of patients with multiple sclerosis and Guillain-Barré syndrome.

Authors:  P G Kennedy; R P Lisak
Journal:  J Neurol Sci       Date:  1979-12       Impact factor: 3.181

9.  the role of autoantibody and immune complexes in the pathogenesis of Guillain-Barré syndrome.

Authors:  S D Cook; P C Dowling
Journal:  Ann Neurol       Date:  1981       Impact factor: 10.422

10.  Myelin-specific proteins and glycolipids in rat Schwann cells and oligodendrocytes in culture.

Authors:  R Mirsky; J Winter; E R Abney; R M Pruss; J Gavrilovic; M C Raff
Journal:  J Cell Biol       Date:  1980-03       Impact factor: 10.539

View more
  1 in total

Review 1.  Immunology of Guillain-Barré syndrome.

Authors:  I Steiner; O Abramsky
Journal:  Springer Semin Immunopathol       Date:  1985
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.